Details for Patent: 8,685,934
✉ Email this page to a colleague
Which drugs does patent 8,685,934 protect, and when does it expire?
Patent 8,685,934 protects XIGDUO XR and FARXIGA and is included in two NDAs.
Protection for XIGDUO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seven patent family members in four countries.
Summary for Patent: 8,685,934
| Title: | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
| Abstract: | The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided. |
| Inventor(s): | Strumph; Paul (Pennington, NJ), Moran; Stephanie (Princeton, NJ), List; James (Princeton, NJ) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
| Application Number: | 13/321,103 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,685,934 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,685,934
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-005 | Jul 28, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-002 | Oct 29, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-001 | Oct 29, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-004 | Oct 29, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-003 | Oct 29, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-001 | Jan 8, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,685,934
| PCT Information | |||
| PCT Filed | May 26, 2010 | PCT Application Number: | PCT/US2010/036120 |
| PCT Publication Date: | December 02, 2010 | PCT Publication Number: | WO2010/138535 |
International Family Members for US Patent 8,685,934
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| China | 102639125 | ⤷ Sign Up | |||
| China | 106075451 | ⤷ Sign Up | |||
| European Patent Office | 2435033 | ⤷ Sign Up | |||
| Japan | 2012528170 | ⤷ Sign Up | |||
| Japan | 2016104753 | ⤷ Sign Up | |||
| Japan | 2017160212 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
